Share 'Capricor Reports Significant Improvements in Duchenne Patients Treated with CAP-1002 Investigational Cell Therapy'
PPMD is excited to learn that Capricor's investigational cell therapy, CAP-1002, is showing significant improvements in people with Duchenne. We look forward to learning more details about this therapy in a community webinar on Wednesday, November 29 at 1pm eastern. Details coming soon!
Read the release from Capricor:
Significant Improvements Reported in Duchenne Muscular Dystrophy Patients Tre…
You can share this blog post in two ways…
Share this link:
Send it with your computer's email program: Email this